α2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 12, 2010, Pages 6688-6699

  Prokosch, Verena ^a   Panagis, Lambros ^b   Volk, Gerd Fabian ^a   Dermon, Caterina ^b   Thanos, Solon ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BRIMONIDINE; CLONIDINE H 3; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE REGULATED PROTEIN; GLUCOSE RELATED PROTEIN 58; LAMININ BINDING PROTEIN; RADIOPHARMACEUTICAL AGENT; RHODOPSIN; STAT3 PROTEIN; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; GRP58 PROTEIN, RAT; LAMININ BINDING PROTEIN 67 KDA, RAT; LAMININ BINDING PROTEIN 67-KDA, RAT; LAMININ RECEPTOR; PROTEIN DISULFIDE ISOMERASE; QUINOXALINE DERIVATIVE;

ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EXPLANT; IN VITRO STUDY; INTRAOCULAR HYPERTENSION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROSCOPY; NERVE CELL CULTURE; NERVE CRUSH; NERVE FIBER GROWTH; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEOMICS; RAT; RETINA EXPLANT; SHAM PROCEDURE; TWO DIMENSIONAL GEL ELECTROPHORESIS; VIDEORECORDING; ANIMAL; DISEASE MODEL; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GLAUCOMA; MASS SPECTROMETRY; METABOLISM; NERVE FIBER; OPTIC NERVE INJURY; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; RETINA; RETINA DEGENERATION; SPRAGUE DAWLEY RAT;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; AUTORADIOGRAPHY; AXONS; CLONIDINE; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLAUCOMA; GLIAL FIBRILLARY ACIDIC PROTEIN; OPTIC NERVE INJURIES; ORGAN CULTURE TECHNIQUES; PLATELET ACTIVATING FACTOR; PROTEIN DISULFIDE-ISOMERASES; PROTEOMICS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, LAMININ; RETINA; RETINAL DEGENERATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79955965446     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4835     Document Type: Article

References (64)

1. Salinas-Navarro M, Alarcon-Martinez L, Valiente-Soriano FJ, et al. Functional and morphological effects of laser-induced ocular hypertension in retinas of adult albino Swiss mice. Mol Vis. 2009;15: 2578-2598.
2. Salinas-Navarro M, Alarcon-Martinez L, Valiente-Soriano FJ, et al. Ocular hypertension impairs optic nerve axonal transport leading to progressive retinal ganglion cell degeneration. Exp Eye Res. 2010;90:168-183.
3. Son JL, Soto I, Oglesby E, et al. Glaucomatous optic nerve injury involves early astrocyte reactivity and late oligodendrocyte loss. Glia. 2010;58:780-789.
4. Soto I, Oglesby E, Buckingham BP, et al. Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. J Neurosci. 2008; 28:548-561.
5. Levin LA. Relevance to the site of injury of glaucoma to neuroprotective strategies. Surv Ophthalmol. 2001;45:243-249.
6. Morrison JC, Johnson EC, Cepurna W, Jia L. Understanding mechanisms of pressure-induced optic nerve damage. Prog Retin Eye Res. 2005;24:217-240.
7. Faber JE, Meininger GA. Selective interaction of alpha-adrenoreceptors with myogenic regulation of microvascular smooth muscle. Am J Physiol. 1990;260:1126-1133.
8. Meininger GA, Faber JE. Adrenergic facilitation of myogenic response in skeletal muscle arterioles. Am J Physiol. 1991;260:1424-1432.
9. Tattoon WG. Maintaining mitochondrial membrane impermeability: an opportunity for new therapy in glaucoma? Surv Ophthalmol. 2001;45:277-283.
10. Weber B, Steinfath M, Scholz J, Bein B. Neuroprotective effects of α2-adrenergic receptor agonists. Drug News Perspect. 2007;20: 149-154.
11. Yoles E, Wheeler LA, Schwartz M. α2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65-73.
12. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci. 2000;41:4169-4174.
13. Lönngren U, Näpänkangas U, Lafuente M, et al. The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment. Brain Res Bull. 2006;11:208-218.
14. Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res. 1992;24:213-219.
15. WoldeMussie E, Wijono M, Pow D. Localization of alpha 2 receptors in ocular tissues. Vis Neurosci. 2007;24:745-756.
16. Ma D, Hossain M, Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004;11:87-97.
17. Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of α2 agonist brimonidine on adult rat retinal ganglion cells after increased intraocular pressure. Brain Research. 2001;913: 133-139.
18. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. α2- Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296:216-223.
19. Lafuente MP, Villegas-Perez MP, Selles-Navarro I, Mayor-Torroglosa S, Miralles de Imperial J, Vidal-Sanz M. Retinal ganglion cell death after acute retinal ischemia is an ongoing process whose severity and duration depends on the duration of the insult. Neuroscience. 2002;109:157-168.
20. Lafuente MP, Villegas-Perez MP, Sobrado-Calvo P, Garcia- Aviles A, Miralles de Imperial J, Vidal-Sanz M. Neuroprotective effects of α2- selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2001;42:2074-2084.
21. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42: 2849-2855.
22. Maier C, Steinberg GK, Sun GH, Zhi GT, Maze M. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology. 1993;79:306-312.
23. Zhang Y. Clonidine preconditioning decreases infarct size and improves neurological outcome from transient forebrain ischemia in the rat. Neuroscience. 2004;125:625-631.
24. Gandolfi SA, Cimino L, Mora P. Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial. Eur J Ophthalmol. 2003;13:611-615.
25. Katsimpris JM, Siganos D, Konstas AG, Kozobolis V, Georgiadis N. Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification. J Cataract Refract Surg. 2003;29:2288-2294.
26. Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new α2- adrenoreceptor agonist for glaucoma treatment. J Glaucoma. 1997;6:250-258.
27. Acheampong A, Shackleton M, John B, Burke J, Wheeler L, Tang- Liu D. Distribution of brimonidine into anterior and posterior tissue of monkey, rabbit and rat eyes. Drug Metab Dispos. 2002; 30:421-429.
28. Wheeler LA, Lai R, WoldeMussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol. 1999; 1:17-21.
29. Lai RK, Chun T, Hasson D, Lee S, Mehrbod F, Wheeler L. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci. 2002;19:175-185.
30. Aviles-Trigueros M, Mayor-Torroglosa S, Garcia-Aviles A, et al. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine. Exp Neurol. 2003;184:767-777.
31. Lafuente Lopez-Herrera MP, Mayor-Torroglosa S, Miralles de Imperial J, Villegas-Perez MP, Vidal-Sanz M. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol. 2002;178:243-258.
32. Lafuente MP, Villegas-Perez MP, Mayor S, Aguilera ME, Miralles de Imperial J, Vidal-Sanz M. Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study. Exp Eye Res. 2002;74:181-189.
33. Mayor-Torroglosa S, De la Villa P, Rodriguez ME, et al. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005;46:3825-3835.
34. Bähr M, Vanselow J, Thanos S. In vitro regeneration of adult rat ganglion cell axons from retinal explants. Exp Brain Res. 1988; 73:393-401.
35. Liedtke T, Schwamborn JC, Schröer U, Thanos S. Elongation of axons during regeneration involves retinal crystallin beta b2 (crybb2). Mol Cell Proteomics. 2007;6:895-907
36. Bonk T, Humeny A. MALDI-TOF-MS analysis of protein and DNA. Neuroscientist. 2001;7:6-12.
37. Krupin T, Feitl M, Roshe R, et al. Halothane anesthesia and aqueous humor dynamics in laboratory animals. Invest Ophthalmol Vis Sci. 1980;19:518-521.
38. O'Farrell PH. High resolution two dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007-4021.
39. Fischer D, Hauk TG, Müller A, Thanos S. Crystallins of the beta/ gamma-superfamily mimic the effects of lens injury and promote axon regeneration. Mol Cell Neurosci. 2008;37:471-479.
40. Naskar R, Thanos S. Detection of early neuron degeneration and accompanying microglial responses in the retina of a rat model glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2962-2968.
41. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature. 1970;227:680-685.
42. Guo GG, Patel K, Kumar V, et al. Association of the chaperone glucose-regulated protein 58 (GRP58/ER-60/ERp57) with Stat3 in cytosol and plasma membrane complexes. J Interferon Cytokine Res. 2002;22:555-563.
43. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33-44.
44. Wheeler LA, Gil DW, Woldemussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45:290-294.
45. Zarbin MA, Wamsley JK, Palacios JM, Kuhar MJ. Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the rat, monkey and human retina. Brain Res. 1986;374:75-92.
46. Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the α2-adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005;89:758-763.
47. Dean JM, Gunn AJ, Wassink G, George S, Bennet L. Endogenous α2-adrenergic receptor-mediated neuroprotection after severe hypoxia in preterm fetal sheep. Neuroscience. 2006;27:142:615-628.
48. Haghir H, Kovac S, Speckmann EJ, Zilles K, Gorji A. Patterns of neurotransmitter receptor distributions following cortical spreading depression. Neuroscience. 2009;10:1340-1352.
49. Pearson T, Frenguelli BG. Adrenoceptor subtype-specific acceleration of the hypoxic depression of excitatory synaptic transmission in area CA1 of the rat hippocampus. Eur J Neurosci. 2004; 20:1555-1565.
50. Mantyh PW, Rogers SD, Allen CJ, et al. Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured centralnervous system in the rat, rabbit, and human. J Neurosci. 1995; 15:152-164.
51. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127:402-406.
52. Lee KY, Nakayama M, Aihara M, Chen YN, Araie M. Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells. Mol Vis. 2010 17;16:246-251
53. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41:9-18.
54. Liu S, Zhang Y, Xie X, et al. Application of two-dimensional electrophoresis in the research of retinal proteins of diabetic rat. Cell Mol Immunol. 2007;4:65-70.
55. Bringmann A, Iandiev I, Pannicke T, et al. Cellular signaling and factors involved in muller cell gliosis: neuroprotective and detrimental effects. Prog Retin Eye Res. 2009;28:423-451.
56. WoldeMussie E, Wijono M, Ruiz G. Müller cell response to laser-induced increase in intraocular pressure in rats. Glia. 2004;47:109-119.
57. Lönngren U, Näpänkangas U, Lafuente M, et al. The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment. Brain Res Bull. 2006;71:208-218.
58. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42: 2849-2855.
59. Jeon GS, Park SW, Kim DW, et al. Glial expression of the 90-kDa heat shock protein (HSP90) and the 94-kDa glucose-regulated protein (GRP94) following an excitotoxic lesion in the mouse hippocampus. Glia. 2004;48:250-258.
60. Maclennan KM, Smith PF, Darlington CL. Platelet-activating factor in the CNS. Prog Neurobiol. 1996;50:585-596.
61. Moriguchi S, Shioda N, Yamamoto Y, Fukunaga K. Plateletactivating factor-induced synaptic facilitation is associated with increased calcium/calmodulin-dependent protein kinase II, protein kinase C and extracellular signal-regulated kinase activities in the rat hippocampal CA1 region. Neuroscience. 2010;166: 1158-1166.
62. Smalheiser NR, Schwartz NB. Cranin: a laminin-binding protein of cell membranes Proc Natl Acad Sci. 1987;84:6457-6461.
63. Smalheiser NR, Schwartz NB. Kinetic analysis of 'rapid onset' neurite formation in NG108-15 cells reveals a dual role for substratum-bound laminin. Brain Res. 1987;431:111-121.
64. Wang YD, Wu JD, Jiang ZL, Wang YB, Wang XH, Liu C, Tong MQ. Comparative proteome analysis of neural retinas from type 2 diabetic rats by two-dimensional electrophoresis. Curr Eye Res. 2007; 32:891-901.